



# Citi Pharma Limited

October 29, 2025

The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi.

**Financial results for the quarter ended September 30, 2025**

Dear Sir,

We have to inform you that the Board of Directors of the company in their meeting held on Wednesday, October 29, 2025 at 1:30 Pm 588 Block Q, Phase 2 Johar Town, Lahore Lahore have Recommended the following.

- |   |     |
|---|-----|
| 1. Cash Dividend                          | Nil |
| 2. Bonus Shares                           | Nil |
| 3. Right Shares                           | Nil |
| 4. Any other entitlement/corporate action | Nil |
| 5. Any other Price sensitive information  | Nil |

Statement of Financial Position, Statement of Profit or loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash flows of the Company for the quarter ended September 30, 2025, are enclosed as annexures.

Yours Sincerely,



**Ghulam Dastgeer**  
Company Secretary

Cc:

**Executive Director/HOD, Offsite-II, Department**

Supervision Division, Securities & Exchange Commission of Pakistan



588 - Q, Johar Town, Lahore - Pakistan



3KM. Head Balloki Road, Phool Nagar, District Kasur - Pakistan



Head Office : +92. 42. 35316587 - 90 | Factory: +92. 49. 4510189, +92. 49. 4513392



www.citipharma.com.pk

**CITI PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)**  
**FOR THE PERIOD ENDED SEPTEMBER 30, 2025**

	SEPTEMBER 30, 2025	SEPTEMBER 30, 2024
	Rupees	Rupees
Sales - net	3,370,247,671	3,224,644,817
Cost of sales	(2,851,274,049)	(2,796,131,798)
Gross profit	518,973,622	428,513,018
Administrative and general expenses	50,188,888	46,396,931
Marketing and distribution expenses	48,429,697	40,695,519
	(98,618,585)	(87,092,449)
Operating Profit	420,355,037	341,420,569
Financial Charges	(121,191,504)	(64,573,618)
	299,163,533	276,846,952
Other income	28,766,096	92,221,819
	327,929,629	369,068,771
Other Expenses	(25,651,370)	(28,770,866)
Profit before income taxes and final taxes	302,278,259	340,297,905
Taxation - Final taxes	-	(4,004)
Profit before income tax	302,278,259	340,293,901
Taxation - Income tax	(98,587,386)	(138,796,883)
Profit after income tax	203,690,873	201,497,017
Earnings per share- basic and dilutive (Rupees)	0.89	0.88



Chief Executive

Chief Financial Officer



Director

**CITI PHARMA LIMITED**  
**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION**  
**AS AT SEPTEMBER 30, 2025**

	Note	(UN-AUDITED) SEPTEMBER 30, 2025 Rupees	JUNE 30, 2025 Rupees
<b>EQUITY AND LIABILITIES</b>			
<b>SHARE CAPITAL AND RESERVES</b>			
Authorised Capital:			
300,000,000 Ordinary shares of Rs. 10/- each		3,000,000,000	3,000,000,000
Share Capital			
Issued, subscribed and paid up capital	4	2,284,612,000	2,284,612,000
Capital Reserves			
Share premium		1,391,532,000	1,391,532,000
Surplus on revaluation of freehold land		5,384,617,300	5,384,617,300
		6,776,149,300	6,776,149,300
Revenue Reserve			
Unappropriated Profit		2,010,508,254	1,806,817,381
		11,071,269,554	10,867,578,681
<b>NON-CURRENT LIABILITIES</b>			
Deferred Liabilities		200,622,710	201,763,862
Deferred Grant		-	-
Lease Liabilities	5	59,899,237	64,864,123
		260,521,947	266,627,986
<b>CURRENT LIABILITIES</b>			
Trade and other payables		3,618,140,272	3,858,531,251
Due to Related Parties		5,686,383	5,686,383
Short Term Borrowings-Secured		2,726,653,482	2,863,211,696
Current portion of long term liabilities		13,907,817	15,802,536
Unclaimed Dividend		4,065,868	4,065,868
Accrued Mark Up		66,984,620	38,268,523
Provision for taxation		99,728,538	519,677,557
		6,535,166,980	7,305,243,814
Contingencies and commitments		-	-
		17,866,958,481	18,439,450,481
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	6	8,679,167,584	8,687,898,852
Long term Security Deposits		25,443,117	25,443,117
Long Term Advance		254,540,900	254,540,900
		8,959,151,601	8,967,882,869
<b>CURRENT ASSETS</b>			
Stock in Trade		3,795,242,159	3,929,701,530
Trade Debts- Unsecured		3,401,435,496	3,078,215,648
Advances, Deposits, prepayments & other Receivables		795,635,749	903,708,936
Short Term Investments		892,345,064	956,388,685
Cash and Bank Balances		23,148,413	603,552,814
		8,907,806,880	9,471,567,612
		17,866,958,481	18,439,450,481

Chief Executive

Chief Financial Officer

Director



## CITI PHARMA LIMITED

## CONDENSED INTERIM STATEMENT OF OTHER COMPREHENSIVE INCOME (UN-AUDITED)

FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	Note	SEPTEMBER 30, 2025 Rupees	SEPTEMBER 30, 2024 Rupees
Profit after income tax		203,690,873	201,497,017
Other comprehensive (loss) / income			
Items that will not be subsequently reclassified in profit or loss:			
Other comprehensive income for the period		-	-
Total comprehensive income for the year		203,690,873	201,497,017

Chief Executive

Chief Financial Officer



Director



CITI PHARMA LIMITED  
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY  
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

PARTICULARS	SHARE CAPITAL	CAPITAL RESERVES		REVENUE RESERVES	TOTAL
		SURPLUS ON REVALUATION OF FREEHOLD LAND	SHARE PREMIUM	UN-APPROPRIATED PROFIT	
----- Rupees -----					
Balance as at June 30, 2024 (Audited)	2,284,612,000	309,294,525	1,391,532,000	1,647,690,917	5,633,129,442
Total Comprehensive income for the period-	-	-	-	201,497,017	201,497,017
Balance as at September 30, 2024- (Un-audited)	2,284,612,000	309,294,525	1,391,532,000	1,849,187,934	5,834,626,459
Balance as at June 30, 2025 (Audited)	2,284,612,000	5,384,617,300	1,391,532,000	1,806,817,381	10,867,578,681
	-	-	-	-	-
Total Comprehensive income for the period-	-	-	-	203,690,873	203,690,873
Balance as at September 30, 2025- (Un-audited)	2,284,612,000	5,384,617,300	1,391,532,000	2,010,508,254	11,071,269,554

Chief Executive

Chief Financial Officer



Director

CITI PHARMA LIMITED  
CONDENSED INTERIM STATEMENT OF CASH FLOWS (UN-AUDITED)  
FOR THE PERIOD ENDED SEPTEMBER 30, 2025

	SEPTEMBER 30, 2025 Rupees	SEPTEMBER 30, 2024 Rupees
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before income taxes and final taxes	302,278,259	340,297,905
<u>Adjustments For Non- Cash Items And Other Line Items:</u>		
Depreciation	46,638,756	41,085,326
Amortization of Deferred Grant	-	(582,494)
Unrealized Loss on Investment in Shares	183,000	(2,703,600)
Accrued Interest	(1,575,744)	(8,541,847)
Financial Charges	121,191,504	64,573,618
Worker's Profit Participation Fund	16,330,968	18,268,904
Worker's Welfare Fund	6,084,086	6,811,274
	188,852,571	118,911,180
Profit before working capital changes	491,130,830	459,209,085
Effect of working capital changes:		
Advances, Deposits And Prepayments	(227,249,403)	47,491,491
Trade Debts	(323,219,848)	(280,189,144)
Stock In Trade	134,459,371	(475,251,059)
Trade and other payables	(190,194,609)	438,015,577
	(606,204,489)	(269,933,135)
Financial Charges Paid	(58,727,936)	(79,796,413)
Income Tax Paid	(217,316,646)	(163,897,944)
Gratuity Paid	-	-
Worker's Profit Participation Fund paid	(72,611,424)	-
	(348,656,006)	(243,694,357)
Net cash flow from operating activities	A (463,729,665)	(54,418,407)
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Property And Equipment	(20,538,251)	(24,092,544)
Capital Work in Progress	(17,369,238)	-
Long Term Security Deposits	-	(3,427,788)
Short Term Investments	63,527,575	-
Net cash flow from investing activities	B 25,620,086	(27,520,333)
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Long-term loans repaid	-	(5,516,511)
Liability Against Assets Subject To Finance Lease	(5,858,718)	(871,597)
Due to Related Parties	-	(14,450,000)
Dividend Paid	-	-
Short Term Borrowings	(136,558,214)	26,200,762
Net Cash flow From financing Activities	C (142,416,932)	5,362,653
Net Increase/ (Decrease) In Cash And Cash Equivalents	A+B+C (580,526,511)	(76,576,087)
Cash And Cash Equivalents At Beginning of the period	1,491,472,244	1,278,333,631
Cash And Cash Equivalents at End Of The period	910,945,733	1,201,757,544
Cash and cash equivalents comprise of:		
Cash in hand	3,865,018	3,584,692
Cash at banks	19,283,395	52,322,179
Short Term Investments	887,797,320	1,145,850,673
	910,945,733	1,201,757,544

Chief Executive

Chief Financial Officer

Director

